Livet, GeneraLife IVF, Torino, Italy.
GynePro Medical, NextClinics International, Reproductive Medicine Unit, Bologna, Italy.
J Assist Reprod Genet. 2022 Jan;39(1):67-73. doi: 10.1007/s10815-021-02364-1. Epub 2021 Nov 30.
To study whether a new combination of different warming kits is clinically effective for vitrified human blastocysts.
This is a longitudinal cohort study analysing two hundred fifty-five blastocysts warming cycles performed between January and October 2018. Embryos were vitrified using only one brand of ready-to-use kits (Kitazato), whereas the warming procedure was performed with three of the most widely used vitrification/warming kits (Kitazato, Sage and Irvine) after patient stratification for oocyte source. The primary endpoint was survival rate, while the secondary endpoints were clinical pregnancy, live birth and miscarriage rates.
We observed a comparable survival rate across all groups of 100% (47/47) in KK, 97.6% (49/50) in KS, 97.6% (41/42) in KI, 100% (38/38) in dKK, 100% (35/35) in dKS and 100% (43/43) in dKI. Clinical pregnancy rates were also comparable: 38.3% (18/47) in KK, 49% (24/49) in KS, 56.1% (23/ 41) in KI, 47.4% (18/38) in dKK, 31.4% (11/35) in dKS and 48.8% (21/ 43) in dKI. Finally, live birth rates were 29.8% (14/47) in KK, 36.7% (18/49) in KS, 46.3% (19/41) in KI, 36.8% (14/38) in dKK, 25.7% (9/35) in dKS and 41.9% (18/43) in dKI, showing no significant differences.
This study confirmed the efficacy of applying a single warming protocol, despite what the "industry" has led us to believe, supporting the idea that it is time to proceed in the cryopreservation field and encouraging embryologists worldwide to come out and reveal that such a procedure is possible and safe.
研究不同升温套件的新组合对玻璃化人类囊胚是否具有临床效果。
这是一项纵向队列研究,分析了 2018 年 1 月至 10 月期间进行的 255 个囊胚升温周期。胚胎仅使用一种即用型试剂盒(Kitazato)进行玻璃化,而根据卵母细胞来源对患者进行分层后,升温过程则使用三种最广泛使用的玻璃化/升温试剂盒(Kitazato、Sage 和 Irvine)进行。主要终点是存活率,次要终点是临床妊娠率、活产率和流产率。
我们观察到所有组的存活率相当,分别为:KK 组 100%(47/47)、KS 组 97.6%(49/50)、KI 组 97.6%(41/42)、dKK 组 100%(38/38)、dKS 组 100%(35/35)和 dKI 组 100%(43/43)。临床妊娠率也相当:KK 组 38.3%(18/47)、KS 组 49%(24/49)、KI 组 56.1%(23/41)、dKK 组 47.4%(18/38)、dKS 组 31.4%(11/35)和 dKI 组 48.8%(21/43)。最后,活产率分别为:KK 组 29.8%(14/47)、KS 组 36.7%(18/49)、KI 组 46.3%(19/41)、dKK 组 36.8%(14/38)、dKS 组 25.7%(9/35)和 dKI 组 41.9%(18/43),无显著差异。
本研究证实了应用单一升温方案的有效性,尽管“行业”引导我们相信这一点,但这一研究支持了在冷冻保存领域继续前进的想法,并鼓励全球胚胎学家站出来,证明这种方法是可行和安全的。